Single-shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies
Crucell N.V. reported new results from its Ebola vaccine studies. The studies, conducted together with the Vaccine Research Center (VRC) of the US National Institutes of Health (NIH) and the US Army Research Institute of infectious diseases (USAMRIID), confirm previously published results showing that a single shot of the vaccine protected monkeys completely against a lethal Ebola challenge. These new results utilized vectors developed with Crucell's adenoviral vector and PER.C6® cell line technology, and show protection at lower doses than previously reported.
The results of the studies were detailed by Dr Nancy Sullivan, head of the VRC's Biodefense Research Section, at a scientific meeting held at USAMRIID in Fort Detrick, Maryland.
"The timely execution of a series of complex vaccine studies with our Ebola vaccine proves the viability and agility of public-private partnerships such as that between Crucell and the VRC," said Crucell's Chief Scientific Officer, Dr Jaap Goudsmit. "The combination of the VRC's Ebola know-how, USAMRIID's ability to perform Ebola-challenge studies and Crucell's vaccine technology was the key to the current success. It augurs well for the field of biodefense, and for future responses to potential infectious disease outbreaks such as the current Marburg crisis."
Crucell recently secured an exclusive license to patents of the NIH for the development and commercialisation of recombinant vaccines against Ebola.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Dr. Robert Gundel joins Amorfix as Vice President, Research & Development
Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103)
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement with GSK
GATC acquires SOLiD DNA Sequencer from Applied Biosystems
MorphoSys Grants ImmunoGen Access to HuCAL GOLD®
CryoLife reports record second quarter revenues
Lifespin partners with the Leipzig Research Center for Civilization Diseases to obtain deep clinical insights for obesity and diabetes
DFG Forschungszentrum für Molekularphysiologie des Gehirns (CMPB) - Göttingen, Germany
Nventa assembles group of international experts for its Clinical and Scientific Advisory Board
Microscopy: Overcoming the traditional resolution limit for the fast co-tracking of molecules - Researchers have developed an innovative method to simultaneously track rapid dynamic processes of multiple molecules at the molecular scale
New tests identify very early changes in Alzheimer's disease before symptoms appear
